- New study results have revealed that the combination of AstraZeneca’s Imfinzi (durvalumab) and Imjudo (tremelimumab) offers a remarkable long-term survival benefit for individuals battling unresectable hepatocellular carcinoma (HCC) without prior systemic therapy or eligibility for localized treatment.
- Analysis showcased at the European Society of Medical Oncology demonstrates that incorporating a single priming dose of Imjudo alongside Imfinzi slashed the risk of death by an impressive 24% when compared to Bayer’s Nexavar (sorafenib). Noteworthy, approximately 19.6% of patients receiving this groundbreaking duo were still alive after five years, a stark contrast to the 9.4% survival rate observed in those on Nexavar.
- The approval of Imfinzi + Imjudo regimen for HCC spans across the U.S., EU (first-line setting), and Japan.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.